Cetrelimab

Monoclonal antibody

Phase 3topline reported

Evidence outlook · registrational

Bladder Cancer: topline reported 2024-09-09

No completed mid-stage readout is on record. The sponsor reported topline results on 2024-09-09 (SunRISe-2 stopped for futility). The announcement is listed under Regulatory events. An earlier registrational trial (SunRISe-2 (NCT04658862)) missed its primary endpoint; the trial rows below carry the recorded results.

Latest reported trial: SunRISe-2 (NCT04658862) · Phase 3 · missed primary endpoint · grade pending

Also in development:Non-Small Cell Lung Cancer · Phase 1/2

Development in Multiple Myeloma stopped for reasons the sponsor has not stated. Development continues in another indication. Source

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Bladder Cancer
Phase 2/3 (1)
Phase 2 (7)
Bladder Cancer
NCT06511648 · Spanish Oncology Genito-Urinary Group
2023-03-07 – 2029-10 · Muscle-invasive Bladder Cancer
What this study did
Other / comorbidity
NCT06534190 · University Medical Center Groningen
2025-03-11 – 2028-11 · Locally Advanced Solid Tumor
What this study did
NCT04592237 · M.D. Anderson Cancer Center
2020-12-29 – 2027-12-31 · Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
What this study did
NCT03431350 · Janssen Research & Development, LLC
2018-03-02 – 2027-12-31 · Prostatic Neoplasms, Castration-Resistant
What this study did
NCT04919512 · Janssen Research & Development, LLC
2022-07-07 – 2026-03-31 · Urinary Bladder Neoplasms
What this study did
NCT04926181 · Rahul Aggarwal
2022-03-16 – 2024-03-31 · Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
What this study did
Phase 1/2 (3)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT03473743 · Janssen Research & Development, LLC
2018-04-05 – 2026-12-31 · Urothelial Carcinoma
What this study did
NCT02908906 · Janssen Research & Development, LLC
2016-11-21 – 2026-12-31 · Neoplasms
What this study did
Phase 1 (8)
Non-Small Cell Lung Cancer
NCT07027514 · Ankyra Therapeutics, Inc
2025-10-22 – 2028-12-31 · Non Small Cell Lung Cancer
What this study did
NCT06116786 · Johnson & Johnson Enterprise Innovation Inc.
2023-11-27 – 2028-01-31 · Carcinoma, Non-small-Cell Lung
What this study did
Other / comorbidity
NCT06311578 · Johnson & Johnson Enterprise Innovation Inc.
2024-04-10 – 2033-02-14 · Neoplasms
What this study did
NCT07525141 · Johnson & Johnson Enterprise Innovation Inc.
2026-05-18 – 2029-01-31 · Neoplasms
What this study did
NCT05818683 · Janssen Research & Development, LLC
2023-04-26 – 2028-05-23 · Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
What this study did
NCT05242445 · Janssen Research & Development, LLC
2022-04-19 – 2023-05-09 · Hepatitis B, Chronic
What this study did
NCT03551782 · Janssen Research & Development, LLC
2018-06-28 – 2021-11-11 · Castration-Resistant Prostatic Neoplasms
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cetrelimab: this drugPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinApprovedAntibody–drug conjugateNectin-4Partial signal
NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74)
NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4)
Nogapendekin Alfa Inbakicept (Anktiva)ApprovedProtein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15Weak signal
NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%.
MK-3120Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-2005Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
TuvutromstatPhase 1Small moleculeMAT2Anot yet gradedNo reviewed efficacy summary in this indication
Avipendekin Pegol
—(overall)
CytokineIL-15 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cetrelimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Bladder CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT04658862 · CT.gov ↗
What to watch
2027 (5)
January 2027 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT05908734 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-14 · NCT06116786 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT07027514 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate CancerRecruiting
Est. primary completion 2027-08-31 · NCT05818683 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT04592237 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-01-12 · NCT07525141 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2Locally Advanced Solid TumorRecruiting
Est. primary completion 2028-11 · NCT06534190 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-11-08 · NCT06311578 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
Phase 3Bladder CancerActive not recruiting
Est. primary completion 2029-09-18 · NCT05714202 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 September 2024Topline resultSunRISe-2 stopped for futility
Johnson & Johnson · Source ↗